Better outcomes for patients with diabetic macular edema

Ophthalmology

Volumn 118, Issue 4, 2011, Pages 607-608

  Schachat, Andrew P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOCINOLONE; PEGAPTANIB; RANIBIZUMAB; STEROID; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

CLINICAL PROTOCOL; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG SAFETY; EDITORIAL; HUMAN; LASER; OFF LABEL DRUG USE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; HUMANS; LASER COAGULATION; MACULAR EDEMA; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79953307461     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.02.021     Document Type: Editorial

References (9)

1. Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
2. Schachat AP. A new approach to the management of diabetic macular edema. Ophthalmology 2010;117:1059-60.
3. Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-14.
4. Mitchell P, Bandello, F, Schmidt-Erfurth U, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25.
5. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35.
6. Chew EY, Ferris FL 3rd, Csaky KG, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003;110:1683-9. (Pubitemid 37025423)
7. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-81.
8. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010;117:2146-51.
9. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-2405.